Table 5.

Blood eosinophil counts and IL5RA expression levels according to asthma diagnosis, sensitization and severity.

	N	Eosinophils/μla (Mean ± SD)	IL5RA, relative expression (Mean ± SD)	P-valueb	P-valuec
Controls	100	127.8 ± 89.4	7.1 ± 6.3
Asthmatic patients	187	380.4 ± 331.0	15.5 ± 15.4	<0.001
Non-allergic asthma (NAA)	76	373.4 ± 367.1	13.9 ± 13.7	<0.001
NAA without NP	33	223.7 ± 169.4	10.3 ± 11.2	0.037	0.047
NAA with NP	43	510.0 ± 441.6	16.6 ± 14.9	<0.001
Allergic asthma (AA)	111	385.6 ± 303.3	16.6 ± 16.4	<0.001
AA without NP	82	308.4 ± 222.9	16.5 ± 17.0	<0.001	0.982
AA with NP	29	577.1 ± 386.9	16.6 ± 15.0	<0.001
Monosensitized to pollens	22	478.7 ± 301.6	20.2 ± 17.3	<0.001
Monosensitized to animal dander	6	300.0 ± 205.2	21.4 ± 29.2	0.050
Monosensitized to mites	10	411.1 ± 513.4	14.5 ± 14.5	0.064
Polysensitized	73	358.8 ± 266.4	15.2 ± 14.7	<0.001
Intermittent asthma	49	290.8 ± 199.3	12.0 ± 13.7	0.003	0.056
Mild persistent asthma	29	337.4 ± 192.7	17.7 ± 18.4	<0.001
Moderate persistent asthma	85	380.5 ± 340.9	15.4 ± 13.4	<0.001
Severe persistent asthma	23	574.0 ± 494.3	19.9 ± 20.3	<0.001
Early-onset asthma	76	364.0 ± 307.4	14.5 ± 14.4	<0.001
Late-onset asthma	111	391.1 ± 346.7	16.1 ± 16.0	<0.001
Non-eosinophilic asthma	32	98.5 ± 66.1	6.6 ± 5.8	0.707	<0.001
Eosinophilic asthma	120	455.6 ± 332.9	18.2 ± 15.4	<0.001

SD, standard deviation.

^aAll P-value results for blood eosinophil counts were significant (P < 0.05) among each patient group vs. controls, except for non-eosinophilic asthma (P = 0.082).

^bP-value obtained for the comparison of IL5RA expression levels from each patient group vs. controls.

^cP-value obtained for comparison of IL5RA expression levels from NAA without NP vs. NAA with NP; AA without NP vs. AA with NP; intermittent asthma vs. severe persistent asthma; and non-eosinophilic asthma vs. eosinophilic asthma, respectively.